Positive allosteric modulators (PAMs) of nicotinic acetylcholine (ACh) receptors (nAChRs) have potential clinical applications in the treatment of nicotine dependence and many neuropsychiatric conditions associated with decreased brain cholinergic activity, and 3-(2-chlorophenyl)-5-(5-methyl-1-(piperidin-4-yl)-1H-pyrrazol-4-yl)isoxazole (CMPI) has been identified as a PAM selective for neuronal nAChRs containing the a4 subunit. In this report, we compare CMPI interactions with low-sensitivity (a4)3(b2)2 and high-sensitivity (a4)2(b2)3 nAChRs, and with muscle-type nAChRs. In addition, we use the intrinsic reactivity of [ 3 H]CMPI upon photolysis at 312 nm to identify its binding sites in Torpedo nAChRs. Recording from Xenopus oocytes, we found that CMPI potentiated maximally the responses of (a4) 3 (b2) 2 nAChR to 10 mM ACh (EC 10 ) by 400% and with an EC 50 of ∼1 mM. CMPI produced a left shift of the ACh concentration-response curve without altering ACh efficacy. In contrast, CMPI inhibited (∼35% at 10 mM) ACh responses of (a4) 2 (b2) 
Introduction
Muscle-and neuronal-type nicotinic acetylcholine (ACh) receptors (nAChRs) are pentameric ligand-gated ion channels with diverse subunit composition, functions, biophysical properties, and pharmacological characteristics (Jensen et al., 2005; Hurst et al., 2013) . Muscle-type nAChRs have a subunit stoichiometry of a 2 bgd or a 2 b«d, whereas neuronal nAChRs are either homopentamers (e.g., a7 nAChR) or heteropentamers (e.g., a4b2 nAChR) and are expressed pre-and/or postsynaptically at cholinergic and other neurotransmitter synapses (Gotti et al., 2009) . Presynaptic neuronal nAChRs are involved in regulation of neurotransmitter release and the modulation of sleep, attention, learning, and memory (Dani and Bertrand, 2007) . In addition, neuronal nAChRs play a central role in the development of nicotine addiction and are implicated in the underlying pathology of neuropsychiatric disorders, including Alzheimer's and Parkinson's diseases (Jensen et al., 2005) .
Drugs that target nAChRs have potential therapeutic uses in the treatment of nicotine addiction and the behavioral symptoms associated with neurodegenerative and neuropsychiatric conditions (Taly et al., 2009; Hurst et al., 2013) . nAChR positive allosteric modulators (PAMs) are a novel class of cholinergic agents that enhance ACh-mediated responses by binding at site(s) distinct from the conserved ACh (orthosteric) binding sites (Bertrand and Gopalakrishnan, 2007; Williams et al., 2011) . nAChR PAMs are characterized by a wide range of chemical structures, and they potentially bind to different sites in an nAChR or selectively to an nAChR subtype (Changeux and Taly, 2008) . PAM binding sites in a muscle nAChR have been identified by photoaffinity labeling at subunit interfaces in the transmembrane domain (TMD; Nirthanan et al., 2008) and extracellular domain (ECD; Hamouda et al., 2013) . In neuronal nAChRs, mutational analyses identified intersubunit sites in the ECD (Seo et al., 2009; Olsen et al., 2013) and an intrasubunit site in the a7 nAChR TMD (Young et al., 2008; daCosta et al., 2011) .
PAMs of the a4b2 nAChR, the most abundant and widely distributed neuronal nAChR subtype, include desformylflustrabromine (dFBr; Sala et al., 2005) , 3-(2-chlorophenyl)-5-(5-methyl-1-(piperidin-4-yl)-1H-pyrrazol-4-yl) isoxazole (CMPI; Albrecht et al., 2008) , and 3-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]benzonitrile (NS9283; Timmermann et al., 2012) (Fig. 1A) . dFBr was isolated from the marine bryozoan Flustra foliacea, whereas CMPI and NS9283 were developed through high-throughput screening and lead optimization of chemical libraries. At submicromolar concentrations, dFBr, CMPI, and NS9283 potentiate ACh-induced responses of a4-containing nAChRs but not a3b2 or a7 nAChRs (Sala et al., 2005; Albrecht et al., 2008; Timmermann et al., 2012) . Because a4 and b2 subunits are known to assemble in two stoichiometries, 3a4:2b2 and 2a4:3b2 (Fig. 1B) , that have distinct pharmacological profiles (Zwart and Vijverberg, 1998; Nelson et al., 2003) , the effects of NS9283 and dFBr were examined at both (a4) 3 (b2) 2 and (a4) 2 (b2) 3 nAChRs (Timmermann et al., 2012; Weltzin and Schulte, 2015) . Whereas dFBr potentiated both a4b2 nAChRs, NS9283 potentiated only (a4) 3 (b2) 2 nAChRs by binding to a site at the a4:a4 interface, which is present only in the (a4) 3 (b2) 2 nAChR and overlaps with a third ACh binding site within the ECD (Harpsøe et al., 2011; Mazzaferro et al., 2011; Eaton et al., 2014) .
To further characterize the mode of interaction of CMPI with neuronal and muscle nAChRs, we used a two-electrode voltage-clamp recording from Xenopus laevis oocytes to compare the interactions of CMPI with (a4) 3 (b2) 2 , (a4) 2 (b2) 3 , and muscle-type nAChRs. We also prepared [ 3 H]CMPI and established that the intrinsic photochemical reactivity of CMPI can be used to identify its binding sites in the ECD and TMD of the muscle-type Torpedo nAChR.
Materials and Methods
Materials. CMPI was a generous gift from Drs. Stefan McDonough and Alessandro Boezio (Amgen Inc., Cambridge, MA; Albrecht et al., 2008) . [ 3 H]CMPI (16 Ci/mmol) was synthesized by custom tritiation (ViTrax, Placentia, CA). dFBr was from Tocris Bioscience R&D (Minneapolis, MN). Acetylcholine chloride, carbamylcholine chloride, and other chemicals were purchased from Sigma-Aldrich (Milwaukee, WI) unless otherwise indicated in the text. Staphylococcus aureus endoproteinase Glu-C (V8 protease) and Lysobacter enzymogenes endoproteinase Lys-C (EndoLys-C) were from MP Biomedical (Santa Ana, CA) and Roche Diagnostics (Indianapolis, IN), respectively.
Torpedo nAChR-rich membranes were isolated from freshly dissected Torpedo californica electric organs as described previously (Middleton and Cohen, 1991) . Final membranes in 38% sucrose and 0.02% sodium azide were stored at 280°C until the day of use, when they were thawed, pelleted by centrifugation, and resuspended in Torpedo physiologic saline (TPS; 250 mM NaCl, 5 mM KCl, 3 mM CaCl 2 , 2 mM MgCl 2 , and 5 mM sodium phosphate, pH 7.0).
nAChR Expression in Xenopus Oocytes. Plasmids with cDNA encoding human a1 (pSPa64T), a4 (pSP64polyA), b1 (pBSII), b2 (pSP64polyA), d [pBS(SK)], and « (pBSII) nAChR subunits were provided by Dr. Jon Lindstrom (University of Pennsylvania, Philadelphia, PA). Plasmids with cDNA encoding Torpedo a1, g, and d (pMXT) and Torpedo b1 (pSP6) were gifts from Dr. Michael M. White (Drexel University College of Medicine, Philadelphia, PA) and Dr. Henry Lester (California Institute of Technology, Pasadena, CA), respectively. Plasmids were linearized with restriction endonucleases [AseI (ha4) and PvuII (hb2), BsaAI (Hd), FspI (ha1 and Tb), ScaI (Hb1), XbaI (Ta, Tg, and Td), and XhoI (H«)], and cRNA transcripts were prepared using SP6 (Torpedo a, b, g, and d subunits; human a1, a4, and b2 subunits) or T3 (human b1, d, and « subunits) mMESSAGE mMACHINE high yield capped RNA transcription kits (Ambion/ Life Technologies, Grand Island, NY) following the manufacturer's protocol.
Adult female X. laevis were purchased from NASCO (Fort Atkinson, WI), and ovarian lobules were surgically harvested following animaluse protocols approved by the Texas A&M Health Sciences Center Institutional Animal Care and Use Committee. The lobules were treated with 3 mg/ml collagenase type 2 (Worthington Biomedical, Lakewood, NJ) with gentle shaking for 3 hours at room temperature in Ca
12
-free OR2 buffer (85 mM NaCl, 2.5 mM KCl, 1 mM MgCl 2 , 5 mM HEPES, pH 7.6). Stage V and VI oocytes were selected, injected with cRNA, and incubated at 18°C in ND96-gentamicin buffer (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 5 mM HEPES, 50 mg/ml gentamicin, pH 7.6) for 24-72 hours to allow receptor expression. Oocytes were injected with 100 ng of a4 and b2 cRNA combined at ratios 9a:1b or 1a:9b to express nAChRs with subunit stoichiometries of 3a:2b or 2a:3b, respectively. For Torpedo and human muscle nAChR, oocytes were injected with 20-50 ng of total mRNA mixed at ratios of 2a:1b:1g:1d and 2a:1b:1d:1«, respectively. Two-Electrode Voltage-Clamp Recording. A standard twoelectrode voltage-clamp technique was used to study the effects of CMPI and dFBr on ACh-induced current responses of a4b2 and muscle nAChR. Xenopus oocytes were perfused with ND96 recording buffer (100 mM NaCl, 2 mM KCl, 1 mM CaCl 2 , 0.8 mM MgCl 2 , 1 mM EGTA, 10 mM Hepes, pH 7.5) and voltage clamped at 250 mV using Oocyte Clamp OC-725B (Warner Instruments, Hamden, CT). Wholecell currents were digitized using Digidata 1550A/Clampex 10.4 (Axon Instruments/Molecular Devices, LLC. Sunnyvale, CA). An automated Top view of a homology model of an a4b2 nAChR containing two a4 and two b2 subunits and a fifth subunit that is either an a4 or b2 subunit. Both (a4) 3 (b2) 2 and (a4) 2 (b2) 3 nAChRs have two ACh binding sites within the ECD at the a4:b2 subunit interfaces, and the (a4) 3 (b2) 2 nAChR has a low-affinity ACh binding site within the ECD at the a4:a4 subunit interface. perfusion system (Warner Instruments) was used to control recording chamber perfusion and drug application. Each recording run included three to six drug applications (10 seconds each) separated by 1-to 4-minute wash intervals. Oocytes were washed with ND96 recording buffer for 3-5 minutes between runs. ACh currents in the absence or presence of CMPI and/or dFBr were quantified using pCLAMP 10.4 (Axon Instruments). For ACh concentration-response curves in the absence or presence of CMPI and/or dFBr, ACh currents were normalized to current elicited by 1000 mM ACh. For calculating the concentration-dependent effects of CMPI and dFBr, ACh currents in the presence of increasing concentrations of CMPI and/or dFBr were normalized to the current elicited by ACh alone. Data (average 6 S.E.) of multiple replicas were plotted and fit using SigmaPlot (Systat Software, San Jose, CA).
Radioligand Binding Assays. [PCP] ) to Torpedo nAChR-rich membranes in TPS were determined using a centrifugation assay (Hamouda et al., 2011 . Using a hand-held lamp (model EB-280C; Spectronics Corp., Westbury, NJ), conditions for photolabeling were determined based upon the observed changes of UV absorption following irradiation of CMPI (20 mM) in TPS at 312 nm, which resulted in a decrease in the 270-nm peak and the formation of a peak at 315 nm with a half-life (t 1/2 ) of 3 minutes. Based upon this result, 3 H incorporation into Torpedo nAChR-rich membranes was examined by photolabeling at 312 nm on an analytical scale. Membrane suspensions (2 mg of protein/ml in TPS supplemented with 1 mM oxidized glutathione; 130 mg of protein and 170 pmol ACh binding sites per condition) were equilibrated with 1 mM [ 3 H]CMPI (1 mCi per condition) for 40 minutes at 4°C and then irradiated on ice for 3 or 6 minutes at a distance of less than 1 cm. The membrane polypeptides were then resolved by SDS-PAGE as previously described (Hamouda et al., 2011) on two parallel 8% polyacrylamide gels. Polypeptides were visualized by Coomassie Blue R-250 stain, and one gel was prepared for fluorography using Amplify (GE Healthcare, Pittsburgh, PA). Polypeptide gel bands were excised from both gels, and H incorporation into nAChR subunits, subsequent analytical and preparative photolabelings were irradiated at 312 nm for 3 minutes.
[ 3 H]CMPI Preparative Photolabeling. Preparative-scale photolabeling, isolation of photolabeled Torpedo nAChR fragments, and identification of photolabeled amino acids by automated Edman protein microsequencing were performed as detailed previously (Chiara et al., 2009; Hamouda et al., 2013) . In brief, Torpedo nAChR-rich membranes (2 mg of protein/ml; 10 mg of protein and ∼13 nmol ACh binding sites per condition) were photolabeled with 1 mM [ 3 H]CMPI (80 mCi per condition) in the absence and presence of 1 mM Carb, and the nAChR subunits were resolved on an 8% SDS-PAGE gel. The nAChR b, g, and d subunits were recovered by passive elution from the gel bands excised from the stained gel and resuspended in digestion buffer (15 mM Tris, 0.5 mM EDTA, 0.1% SDS, pH 8.1). The gel bands containing the [ 3 H]CMPI-photolabeled nAChR a subunit were excised and transferred to 15% polyacrylamide mapping gels and subjected to in-gel digestion with 100 mg of V8 protease to generate nAChR a subunit fragments (aV8-20, aV8-18, aV8-10, and aV8-4; Blanton and Cohen 1994) that were recovered from the gel and resuspended in digestion buffer. Greater than 95% of the Carb-inhibitable 3 H cpm was recovered in aV8-20, which begins at aSer 173 and contains the core aromatics aTyr 190 and aTyr 198 of ACh binding site segment C and transmembrane helices M1-M3. aV8-20 was digested for 2 weeks with 0.5 units of EndoLys-C, and the digest was then fractionated using reverse-phase high-performance liquid chromatography (rpHPLC). All radioactivity in that rpHPLC fractionation eluted as a single, Carb-inhibitable peak centered at ∼80% organic in three fractions which were pooled and loaded onto glass fiber filters for sequencing on a PROCISE 492 protein sequencer (Applied Biosystems, Foster City, CA). At each cycle of Edman degradation, 1/6 was used for amino acid identification/quantification and 5/6 for 3 H counting. Photolabeling efficiency (in cpm/pmol) was calculated using the
, where x is the cycle number, I 0 is the initial mass of the peptide sequenced, and R is the repetitive yield of Edman degradation.
[
3 H]CMPI-photolabeled g nAChR subunits were digested for 18 hours at room temperature with 200 mg of V8 protease or for 2 weeks with 0.5 units of EndoLys-C. When the V8 digest was fractionated by rpHPLC, the peak of 3 H was recovered in fractions centered at ∼40% organic known to contain the g subunit fragment beginning at gVal ; Chiara and Cohen, 1997) . When the EndoLys-C digest was fractionated by smallpore Tricine-SDS PAGE (Schagger and von Jagow, 1987; Hamouda et al., 2013 ), the peak of 3 H was recovered in a gel band with an Fig. 2 . ACh concentration-response curves of (a4) 3 (b2) 2 and (a4) 2 (b2) 3 nAChRs. Xenopus oocytes injected with nAChR subunit mRNAs mixed at a ratio of 9a4:1b2 [m, (a4) 3 (b2) 2 nAChR] or 1a4:9b2 [d, (a4) 2 (b2) 3 nAChR] were voltage clamped at 250 mV, and currents elicited by 10-second applications of increasing concentrations of ACh were recorded. (A) Representative traces of ACh-induced current responses of (a4) 3 (b2) 2 and (a4) 2 (b2) 3 nAChRs. For each concentration, the peak currents were normalized to the peak current elicited by 1 mM ACh, and averages (6S.E.) of replicas from multiple oocytes (m, 4; d, 6) were plotted (B) and fit to a three-parameter Hill equation (Materials and Methods, eq. 1). ACh EC 50 values/Hill coefficients for (a4) 3 (b2) 2 and (a4) 2 (b2) 3 nAChRs were 160 6 24 mM/0.9 6 0.1 and 1.1 6 0.04 mM/1.260.04, respectively.
A Photoreactive PAM of (a4) 3 (b2) 2 nAChR apparent molecular mass of ∼24 kDa. When that material was further purified by rpHPLC, all 3 H eluted as a broad peak (∼60% organic), which was identified by N-terminal sequencing as the fragment beginning at gGlu 47 that contains ACh binding site segment D (gTrp 55 ; Chiara and Cohen, 1997) .
[ 3 H]CMPI-photolabeled nAChR d subunits were digested for 2 weeks with 0.5 units of EndoLys-C. The digest was fractionated by Tricine SDS-PAGE, and material eluted from gel bands with apparent molecular masses of ∼21 and 14 kDa was fractionated by rpHPLC (Garcia et al., 2007) . For the 14-kDa band, the major peak of 3 H eluted at ∼70% organic, the region known to contain the fragment beginning at dMet 257 , the N terminus of the dM2 transmembrane helix (Arevalo et al., 2005) . For the 21-kDa band, the major peak of 3 H eluted at ∼50% organic and was identified by sequence analysis as the fragment beginning at Glu 47 that contains ACh binding site segment D (dTrp 57 ) (Wang et al., 2000) .
Data Analyses. Data analyses and parameter calculations were performed using SigmaPlot version 11 (Systat Software). ACh Fig. 3 . CMPI potentiates low-sensitivity (a4) 3 (b2) 2 but not high-sensitivity (a4) 2 (b2) 3 nAChRs. Xenopus oocytes expressing human (a4) 3 (b2) 2 (m) or (a4) 2 (b2) 3 (d, s) nAChRs were voltage clamped at 250 mV, and currents elicited by 10-second applications of 10 mM ACh (d, m) or 3 mM ACh (s) were recorded in the absence or presence of CMPI (A-D) or dFBr (E and F). Shown in (A and B) are representative traces of the effects of CMPI on ACh-induced current responses of (a4) 3 (b2) 2 and (a4) 2 (b2) 3 nAChRs, respectively. (C-F) At each PAM concentration, the current response was normalized to the current elicited by ACh alone, and the average 6 S.E. of responses from multiple oocytes [11 (C); 3 (d), 4 (s) (D); 14 (E); 5 (F)] is plotted. Potentiation data (C, E, and F) were fit to a three-parameter equation (eq. 2). Inhibition data (D) were fit to a single site model of inhibition (eq. 3). (C) The concentration dependence of CMPI potentiation of the (a4) 3 (b2) 2 nAChR was characterized by EC 50 = 0.26 6 0.05 mM, n = 1.2 6 0.2, and I max = 314 6 17%. CMPI also potentiated responses of (a4) 3 (b2) 2 nAChR to 1 mM ACh (three oocytes; data not shown) with EC 50 = 0.4 6 0.03 mM, n = 1.4 6 0.2, and I max = 238 6 8%. (D) CMPI at 10 mM inhibited (a4) 2 (b2) 3 nAChR by 39 6 3% with IC 50 = 0.6 6 0.2 mM. (E) dFBr potentiation of (a4) 3 (b2) 2 nAChRs was characterized by EC 50 = 0.36 6 0.02 mM, n = 1.6 6 0.2, and I max = 417 6 7%. (F) dFBr potentiation of (a4) 2 (b2) 3 nAChRs was characterized by EC 50 = 1.6 6 0.04 mM, n = 1.2 6 0.03, and I max = 304 6 4%. (a4) 3 (b2) 2 nAChRs in the absence (n) and presence of 1mM dFBr (m). For each ACh concentration (2/+ drug), the current was normalized to the current elicited by 1000 mM ACh in the same oocyte. Averages (6S.E.) for responses from multiple oocytes [14 (n), 12 (m) (B); 6 (n), 4 (m)] were plotted and fit to eq. 1. Values of ACh (EC 50 /n/I max ) were as follows: ACh (control), 92 6 17 mM/0.8 6 0.07/110 6 6%; ACh (+CMPI), 0.7 6 0.2 mM/0.6 6 0.1/97 6 4% (B); ACh (control), 190 6 30 mM/0.73 6 0.04/130 6 6%; ACh (+1 dFBr), 139 6 112 mM/0.43 6 0.06/339 6 52% (D). For high-sensitivity (a4) 2 (b2) 3 nAChRs (not shown), the effect of dFBr on the ACh concentration response was characterized by ACh EC 50 /n/I max values of 1.4 6 0.08 mM/1.2 6 0.08/111 6 1.4% (2dFBr) and 2.3 6 0.05 mM/0.8 6 0.1/464 6 23% (+dFBr).
concentration-response curves in the absence or presence of CMPI and/or dFBr were fit to a three-parameter Hill equation:
where I x is the current at ACh concentration x, normalized to the current at 1 mM ACh; I max is the maximum current response; n is the Hill coefficient; and EC 50 is the ACh concentration producing 50% of the maximum response. The concentration-dependent potentiation of ACh-induced currents by CMPI or dFBr was fit to a three-parameter Hill equation:
where I x is the ACh current in the presence of PAM at concentration x, normalized to the current in the absence (as percentage), I max is the maximum potentiation of current (as percent control); n is the Hill coefficient; and EC 50 is the PAM concentration producing 50% maximal potentiation. CMPI inhibition of ACh-induced currents in muscle-type nAChRs and CMPI inhibition of [ 
where f x is ACh-induced current or specific [ 3 H]PCP binding in the presence of CMPI at concentration x, and IC 50 is the CMPI concentration producing 50% inhibition.
Results
CMPI Potentiates Low-Sensitivity (a4) 3 (b) 2 but Not High-Sensitivity (a4) 2 (b) 3 nAChRs. Initial characterization of CMPI as an nAChR PAM established that it potentiated responses of a4b2 nAChRs expressed in human embryonic kidney cells to submaximal doses of nicotine or ACh (Albrecht et al., 2008) . To further characterize the pharmacological profile of CMPI at a4b2 nAChRs, we used two-electrode voltage-clamp recording from Xenopus laevis oocytes to characterize the effects of CMPI on the ACh responses of (a4) 3 (b2) 2 (low ACh sensitivity) and (a4) 2 (b2) 3 (high ACh sensitivity) nAChR isoforms. Expression of (a4) 3 (b2) 2 (ACh EC 50 5 160 6 24 mM) and (a4) 2 (b2) 3 (ACh EC 50 5 1.14 6 0.04 mM) nAChRs was achieved by injecting oocytes with a mixture of a4 and b2 mRNAs at ratios of 9a4: 1b2 or 1a4:9b2, respectively (Fig. 2) . For (a4) 3 (b2) 2 nAChRs, Fig. 5 . CMPI and dFBr act independently to potentiate low-sensitivity (a4) 3 (b2) 2 nAChRs. (A and B) Representative current responses elicited by 10 mM ACh (A) or 1000 mM ACh (B) in the absence and presence of CMPI and/or dFBr. (C) ACh concentration response in the absence (n) and presence of 1 mM CMPI and 1 mM dFBr (j). For each ACh concentration (2/+ drug), the current was normalized to the current elicited by 1000 mM ACh in the same oocyte. Average (6S.E.) from multiple oocytes [n (9), j (8)] were plotted and fit to eq. 1. Values of ACh (EC 50 /n/I max ) were as follows: ACh (control), 106 6 29 mM/0.62 6 0.06/124 6 7%; ACh (+CMPI +dFBr), 0.20 6 0.04 mM/1.2 6 0.3/223 6 8%. Fig. 6 . CMPI inhibits muscle-type nAChRs. Xenopus oocytes injected with mRNA for human muscle (2a:1b:1d:1«; ,) or Torpedo (2a:1b:1g:1d; m) nAChR were voltage clamped at 250 mV, and currents elicited by 10-second applications of 10 mM ACh were recorded in the absence or presence of increasing concentrations of CMPI. Shown in (A) and (B) are representative traces for human a 2 b1«d and Torpedo a 2 b1gd nAChRs. (C) Currents were normalized to the peak current elicited by 10 mM ACh alone, and averages (6S.E.) of multiple replicas from six oocytes were plotted and fit to a single site inhibition model (eq. 3). CMPI inhibited human muscle and Torpedo nAChR with IC 50 values of 0.7 6 0.05 and 0.2 6 0.03 mM, respectively.
A Photoreactive PAM of (a4) 3 (b2) 2 nAChR CMPI, when coapplied, enhanced the response to 10 mM (EC 10 ) ACh, producing a maximal potentiation (I max ) of 314 6 17% with an EC 50 of 0.26 6 0.05 mM (Fig. 3, A and C) . In oocytes expressing (a4) 2 (b2) 3 nAChRs, CMPI (0.01-10 mM) did not enhance current responses for 1, 3, or 10 mM ACh. Instead, CMPI reduced the ACh response, maximally by ∼35% at 10 mM CMPI (Fig. 3, B and D) . In contrast to the selective potentiation of (a4) 3 (b2) 2 nAChRs by CMPI, in the same oocytes, dFBr enhanced ACh responses of (a4) 2 (b2) 3 nAChRs (Fig. 3 , B and F; EC 50 5 1.6 6 0.05 mM; I max 5 304 6 4%) as well as (a4) 3 (b2) 2 nAChRs ( Fig. 3E ; EC 50 5 0.36 6 0.02 mM; I max 5 417 6 7%).
When coapplied with ACh to oocytes expressing (a4) 3 (b2) 2 nAChRs, CMPI at 1 mM produced a left shift of the ACh concentration response, decreasing EC 50 from 92 617 mM to 0.760.2 mM without any change in the maximum response (I max 5 97 6 4%) (Fig. 4, A and B) . This effect of CMPI on the ACh concentration response is similar to that of NS9283 (Olsen et al., 2013) but differs from that of dFBr, which potentiated responses for 1 mM ACh (Fig. 4C) with an EC 50 of ∼0.3 mM, i.e., a value similar to that seen for 10 mM ACh (Fig.  3E) . dFBr increased the ACh maximal response (I max 5 339 6 52%) with little effect on ACh potency (Fig. 4D) .
The differences between CMPI and dFBr in terms of a4b2 nAChR isoform selectivity and their effects on the ACh responses led us to examine the effect of CMPI on (a4) 3 (b2) 2 nAChR potentiation by dFBr and vice versa. In the presence of 1 mM CMPI, a concentration that alone elicited maximum potentiation of the ACh response at submaximal concentrations, dFBr still produced a further potentiation of ACh at 10 mM (EC 10 ; Fig. 5A ) or at 1 mM (Fig. 5B) . Simultaneous application of 1 mM CMPI and 1 mM dFBr produced a left shift in the ACh concentration-response curve, increasing ACh potency by ∼100-fold and increasing efficacy (I max 5 223 6 8%) (Fig. 5C ). These results indicate that CMPI and dFBr bind at different sites and act independently to enhance the potency or efficacy of ACh at (a4) 3 (b2) Aliquots of nAChRs from each photolabeling condition were resolved on two parallel SDS-PAGE gels, and polypeptide bands were excised from both gels for 3H quantification by liquid scintillation counting. Data for Carb, BgTx, and CMPI conditions are average 6 1/2 range of gel bands excised from the two parallel gels. Data for the control condition are average 6 S.D. of four gel bands from the two parallel gels. described in Materials and Methods. To examine the pharmacological specificity of [ 3 H]CMPI photoincorporation into the nAChR, Torpedo nAChR-rich membranes were photolabeled with [
3 H]CMPI (1 mM) in the absence (no drug added) and presence of 1 mM Carb, 2 mM BgTx, or 100 mM CMPI, and covalent incorporation within the subunits was determined by SDS-PAGE followed by fluorography or liquid scintillation counting (Fig. 8) . In the absence of any other drug, [ 3 H]CMPI photoincorporated most prominently into the nAChR a, b, and g subunits and into non-nAChR proteins that bind to the nAChR (Rn, rapsyn) or are present in contaminating membrane fragments [calelectrin (37K), a member of the annexin family of Ca 21 -binding proteins, and the a subunit of Na 1 /K 1 -ATPase (90K)] (Blanton et al., 2001 ). Photolabeling of a and g nAChR subunits was reduced by the same extent (∼50%) in the presence of Carb, BgTx, or CMPI, indicating that a major component of subunit photolabeling was likely to be within the amino acids contributing to the ACh binding site at the a:g subunit interface. Photolabeling in the nAChR d subunit, which contributes to the ACh binding site at the a:d subunit interface, was ∼30% that of the g subunit and was decreased by ∼10 and 20% in the presence of BgTx and CMPI, respectively.
[ 3 H]CMPI Photolabeling of Agonist Binding Sites. The ACh binding sites of the muscle-type nAChR are located within the ECD at the two a subunit interfaces with adjacent g and d subunits. Core aromatic residues contributing to the ACh binding sites are located in three distinct regions within the primary sequence of the a subunit (segments A, B, and C) that contribute to the principal surface of the binding pocket, and amino acids that contribute to the complementary surface are located in three regions within the g or d subunits (segments D, E, and F) (Brejc at al. 2001; Changeux and Taly, 2008) . To identify amino acids photolabeled within the a subunit, the [ 3 H]CMPI-photolabeled a subunit was subjected to in-gel digestion with V8 protease (data not shown). The majority (.95%) of Carb-inhibitable 3 H was contained with aV8-20, which begins at aSer 173 and contains the core aromatics in ACh binding site segment C (aTyr 190 /aTyr 198 ) and transmembrane helices M1-M3. When the subunit fragment beginning at aHis 186 was isolated from an EndoLys-C digest of aV8-20 and sequenced (Fig. 9A) 
Discussion
In this report, we demonstrate that CMPI, a potent PAM selective for nAChRs containing the a4 subunit (Albrecht et al., 2008) , potentiates responses of (a4) 3 (b2) 2 (low-sensitivity) nAChRs, but not (a4) 2 (b2) 3 (high-sensitivity) nAChRs. By recording from Xenopus oocytes expressing (a4) 3 (b2) 2 , (a4) 2 (b2) 3 , or muscle-type (a 2 b«d or a 2 bgd) nAChRs, we found that CMPI enhances ACh potency of (a4) 3 (b2) 2 nAChRs without changing ACh efficacy (maximal response). At concentrations producing a maximal enhancement of (a4) 3 (b2) 2 nAChR responses, CMPI acts as an allosteric inhibitor of (a4) 2 (b2) 3 nAChRs and of human (a 2 b«d) and Torpedo (a 2 bgd) muscle-type nAChRs. In the Torpedo nAChR, CMPI binds with .30-fold higher affinity in the ion channel than in the agonist binding sites. Identification of the Torpedo nAChR amino acids photolabeled by [ 3 H]CMPI confirmed binding in the ion channel and the ACh binding sites, and no evidence was found of photolabeling of other sites in the nAChR ECD or TMD. However, the fact that CMPI photoincorporated into valine and serine side chains in the ion channel and into tyrosines and tryptophans in the ACh binding sites demonstrates that CMPI is a photoreactive PAM possessing broad amino acid side-chain reactivity, which makes it well suited to identify PAM binding sites in neuronal nAChRs.
Pharmacology of CMPI at a4b2 nAChRs. The selective potentiation of (a4) 3 (b2) 2 nAChRs indicates that the a4:a4 interface is required for CMPI binding and/or modulation of channel gating. In addition to CMPI, physostigmine (a nonselective nAChR PAM) and NS9283 [a PAM selective for nAChRs containing a2 and a4 subunits (Timmermann et al., 2012) ] also require the presence of an a4:a4 subunit interface for a4b2 nAChR potentiation (Olsen et al., 2013 (Olsen et al., , 2014 Jin et al., 2014) . Although there is no established relationship between the location of a PAM binding site and its effect on ACh responses, these nAChR PAMs with a4:a4 subunit interface selectivity each increase ACh potency without altering the ACh maximal response (Pandya and Yakel, 2011; Olsen et al., 2013) , similar to the effect of benzodiazepines on GABA responses in abg GABA type A receptors (Sigel and Steinmann, 2012) .
In contrast, consistent with previous results (Kim et al., 2007; Weltzin and Schulte, 2015) , we found that dFBr potentiates both (a4) 3 (b2) 2 and (a4) 2 (b2) 3 nAChRs, increasing ACh maximal responses with little effect on ACh EC 50 . We also found that CMPI at 1 mM, a concentration that produces maximal potentiation, did not prevent further potentiation of (a4) 3 (b2) 2 nAChR by dFBr and vice versa (Fig. 5, A and B) . The effects of both CMPI (decreased ACh EC 50 ) and dFBr (increased ACh maximal response) were maintained when CMPI and dFBr were coapplied with ACh (Fig. 5C ). These results indicate that CMPI and dFBr potentiate (a4) 3 (b2) 2 nAChR by independent mechanisms. They also establish the presence of at least two classes of PAM binding sites within a4b2 nAChRs: one at the a4:a4 subunit interface that mediates potentiation by CMPI, and one or more at the a4:b2 and/or b2:a4 subunit interface that mediate potentiation by dFBr. In a4b2 nAChRs, there can be a single binding site per receptor for PAMs such as CMPI and NS9283, which are selective for (a4) 3 (b2) 2 nAChRs and bind at the a4-a4 subunit interface. For NS9283, mutational analyses predicted a binding site in the ECD at the a4:a4 subunit interface that overlaps with the third ACh binding site in that receptor (Olsen et al., 2013) . However, further studies will be required to determine whether, in the (a4) 3 (b2) 2 nAChR, CMPI binds to the same site as NS9283. For PAMs such as dFBr that potentiate (a4) 2 (b2) 3 and (a4) 3 (b2) 2 nAChRs, there will be at least two binding sites within a receptor, either at subunit interfaces (intersubunit sites) or within a subunit's helix bundle (intrasubunit sites). In agreement with this, substitutions of an amino acid within the b subunit ECD that projects into the b-a interface (two per receptor) reduced a4b2 nAChR potentiation by dFBr (Weltzin and Schulte, 2015) .
[ 3 H]CMPI Is an nAChR Photoreactive Probe. Photoaffinity labeling and protein microsequencing techniques have been used extensively for identification of amino acids contributing to drug binding sites in many targets (Vodovozova, 2007; Das, 2011) , including muscle-type nAChR binding sites for orthosteric ligands, channel blockers, and allosteric modulators (Hamouda et al., 2014; Forman et al., 2015) . Photoaffinity labeling identifies amino acid residues within the protein structure that are in direct contact with a bound drug and differentiates them from amino acids not contributing to the binding site but important for drug action, which can be identified by mutational analyses. Even though CMPI bound with .30-fold higher affinity in the Torpedo nAChR ion channel than in the transmitter binding sites, 55 in the g subunit, suggests that CMPI binds preferentially to the ACh binding site at the a-g interface, as is seen for d-tubocurarine, the classic muscle-type nAChR competitive antagonist, which photolabels the same amino acids in the ACh binding site as CMPI (Chiara and Cohen, 1997; Chiara et al., 1999 (Chiara and Cohen, 1997; Nirthanan et al., 2005; Srivastava et al., 2009 (Hamouda et al., 2013 (Hamouda et al., , 2015 , which indicates that CMPI does not bind to the dFBr/ physostigmine/galanthamine allosteric sites in the ECD at the a/g subunit interface near the entry of the ACh binding site or in the vestibule of the ion channel.
Our results establish that CMPI is a PAM that can photoincorporate into aliphatic as well as nucleophilic amino acid side chains, but we can only speculate on the photoreactive intermediates formed upon irradiation at 312 nm. CMPI has a complex ring structure (Fig. 1) containing piperidine, chlorobenzene, and pyrazole isoxazole rings. CMPI photoincorporation into valine in the ion channel indicates the likely involvement of a radical intermediate, whereas reactions with serines or aromatic amino acid side chains can occur via radical or electrophilic intermediates. The 3,5-disubstituted isoxazole ring forms a reactive azirine intermediate upon irradiation at 313 nm or shorter wavelengths (Price and Ratajczak, 1984) , and UV irradiation of pyrazoles at wavelengths below 250 nm results in H-atom loss and formation of radical intermediates (King et al., 2010) . Similarly, photodehalogenation (C-Cl cleavage) of the chlorobenzene ring would form a radical intermediate with broad amino acid side-chain reactivity. Even in the absence of further definition of CMPI's photoreactive intermediates, the fact that it photoincorporates into a broad range of amino acid side chains makes it well suited for use in the identification of its binding sites in (a4) 3 (b2) 2 nAChRs, where it acts as a PAM, and in (a4) 2 (b2) 3 nAChRs, where it acts as a negative allosteric modulator.
